Kymera Therapeutics vs Xencor
Xencor is the larger business, with $126m of revenue in fiscal 2025 against $39.2m for Kymera Therapeutics (3.2 times as much). Xencor grew faster (13.7% against -16.7%). Xencor kept more of each dollar of sales as profit: a net margin of -73.2% against -794.0%.
| Latest fiscal year | Kymera TherapeuticsKYMR, 2025 | XencorXNCR, 2025 |
|---|---|---|
| Revenue | $39.2m | $126m |
| Revenue growth | -16.7% | 13.7% |
| Net income | −$311m | −$91.9m |
| Operating margin | -891.1% | — |
| Net margin | -794.0% | -73.2% |
| Return on equity | -25.8% | -14.0% |
| Free cash flow | −$234m | −$138m |
| Cash | $357m | $54.1m |
| Total debt | $0 | $120m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 238 | 260 |
| Market value | $10.94bn | $2.29bn |
| Price vs our value range | — | — |
| Moat score | 14 (Weak) | 11 (Weak) |
| Insider trades, 12 months | 2 buys, 274 sales | 0 buys, 18 sales |